Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 14/20 | 0.49 |
| ▸ | ATM | Q13315 | 7/20 | 0.49 |
| ▸ | PRKDC | P78527 | 3/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | LDHB | P07195 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10119825 | 0.79 | ATR (0.44) | ATRATMPRKDCGSK3B | |
| SCHEMBL557954 | 0.78 | ATR (0.72) | ATRATMPRKDCGSK3B | |
| SCHEMBL10309120 | 0.76 | ATR (0.44) | ATRATMPRKDCGSK3BCA12 | |
| SCHEMBL2637980 | 0.73 | ATR (0.43) | ATRATMPRKDCGSK3B | |
| SCHEMBL10119821 | 0.73 | ATR (0.47) | ATRATMPRKDCGSK3B | |
| SCHEMBL16420502 | 0.72 | ATR (0.68) | ATRATMPRKDCGSK3BCA1 | |
| SCHEMBL10119806 | 0.71 | ATR (0.48) | ATRATMPRKDCGSK3B | |
| SCHEMBL2641655 | 0.71 | ATR (0.69) | ATRATMPRKDCGSK3B | |
| SCHEMBL14927218 | 0.71 | ATR (0.47) | ATRATMPRKDCGSK3B | |
| SCHEMBL10119808 | 0.71 | FYN (0.53) | ATRATMPRKDCGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035408-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035408-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885ATM 41/4885PRKDC 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.